erythromycin NDC 75907-076

NDC codes

FDA NDC Directory

Product NDC (as listed)75907-076Labeler and product segments. Claims need a package NDC.

Product NDC at billing width75907-0076Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
75907-076-01	75907007601	100 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC (75907-076-01)Marketed from Sep 1, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): erythromycin
Generic name (nonproprietary): erythromycin
Active ingredients: Erythromycin — 250 mg/1
Dosage form: Capsule, Delayed release pellets
Route: Oral
Labeler: Dr. Reddy's Labratories Inc.
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 050536
Marketing start: Sep 1, 2024
Marketing end: Feb 28, 2027
Other FDA classes: Decreased Sebaceous Gland Activity (Physiologic effect)Macrolides (Chemical structure)
Identifiers: Product ID 75907-076_3657e1bd-fd4f-ba88-c3af-bddb79a2e594SPL ID 3657e1bd-fd4f-ba88-c3af-bddb79a2e594SPL set ID a2dcb48a-212c-1b0c-ec35-ee2ade85847fRxCUI 310154UNII 63937KV33D
Pharmacologic class: Macrolide Antimicrobial; Macrolide

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N475907007601 followed by a unit qualifier and the quantity

Package 75907-0076-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 25, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes. Listeriosis cause…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)